After recently signing an anti-inflammatory deal with Ablynx, AbbVie has now announced a new agreement with Galapagos in cystic fibrosis. Specifically, the organisations have confirmed that they will contribute technologies and resources to develop oral drugs that address the main mutations in cystic fibrosis patients, including F508del and G551D, with the intention of starting Phase
Only Medics will be hosting a day of workshops for medics looking to transition to the pharmaceutical industry. The workshop will take place on Thursday 26th September in Reading, UK. Attendance to the workshop is by invitation only. In addition to medics, the workshop will be attended by industry physicians and HR professionals, some of whom are actively
AstraZeneca have announced that they have licensed a drug which is currently in mid-stage clinical studies for ovarian cancer from Merck & Co. The agreement revolves around MK-1775, an oral small molecule inhibitor of WEE1 kinase, a cell cycle checkpoint protein regulator. Preclinical results have indicated that disruption of WEE1 may improve the cell killing
Japan’s Otsuka has agreed to purchase cancer specialist, Astex Pharmaceuticals, in a deal which is valued at $886 million. Otsuka will obtain the remaining shares of Astex for $8.50 per share in cash, signifying a 48% premium to the average closing stock price for the prior 30-day period. One of the main reasons behind the
Shares in Incyte increased by almost 34% yesterday after the company announced promising mid-stage data for their pancreatic cancer therapy, Jakafi. Positive results from a Phase II clinical trial showed that the JAK inhibitor, Jakafi (ruxolitinib), when used in combination with Roche’s Xeloda (capecitabine), improved survival in some patients with recurrent or treatment refractory advanced
Amgen have confirmed a new partnership with Servier to boost the pipelines of both businesses. The waiting period to let any antitrust concerns to arise has now passed, meaning the two companies can advance with the agreement. The deal will provide Amgen with rights in the US to Servier’s heart drug, ivabradine, which has already
Novo Nordisk has announced another strong set of results, aided by strong sales of their diabetes drug, Victoza. The company’s net profit for the second quarter increased by 26% to 6.73 billion Danish kroner (equal to roughly $1.20 billion), while sales grew 10% to 21.38 billion kroner. The organisation’s group of modern insulin products, including
Icon have announced that they have reviewed their guidance for revenues and earnings per share in fiscal year (FY) 2013 after posting another strong financial quarter. Earlier this week, Icon reported net revenues for their second quarter of US $334.2 million, an increase of 20.6% year on year, comfortably passing the forecast of US $321.8
Eli Lilly yesterday posted a strong set of financials for the second quarter of 2013, and announced that they would be raising their forecast for the full-year. The Q2 results were aided by cost-cutting and strong sales of their blockbuster drug, Cymbalta. Net income soared by 36% to $1.25 billion, while turnover increased 6% to
Johnson & Johnson have reported strong results for their second quarter of 2013, with an 8.5% increase in sales. The increase was aided by robust results from their prostate cancer drug, Zytiga. Net income reached $3.83 billion, a major increase from the $1.41 billion from the previous year’s quarter 2 period, aided by the gain
